Faculty

Faculty Details


Faculty Details

  • Name: Dr. Shyam Lal M
  • Mail: shyamlal_abslsuohyd.ac.in
  • Contact:
  • Area Of Research:Infectious Disease Biology and Nanobiotechnology

EDUCATION

  • Ph.D. (Biochemistry), Banaras Hindu University. 
  • M.Sc. (Biochemistry), University of Hyderabad.
  • B.Sc. (Biotechnology), Osmania University.
PROFESSIONAL EXPERIENCE
  • Oct 2023 (onwards): Associate Professor, Department of Animal Biology, School of Life Sciences, UoH.
  • Jan 2023 – Oct 2023: Scientist D, Infectious Disease Biology Laboratory, Chemical Biology Unit, Institute of Nano Science and Technology, Sector 81, Knowledge City, Mohali, Punjab (140306), India.
  • Jan 2019 – Dec 2022: Scientist C, Infectious Disease Biology Laboratory, Chemical Biology Unit, Institute of Nano Science and Technology, Sector 81, Knowledge City, Mohali, Punjab (140306), India.
  • Feb 2015 – Dec 2018: Scientist B, Infectious Disease Biology Laboratory, Chemical Biology Unit, Institute of Nano Science and Technology, Sector 81, Knowledge City, Mohali, Punjab (140306), India.
AWARDS
  • Early Career Research Award (2016) from Science and Engineering Board, Department of Science and Technology, Govt. of India.

No Records Available
No Records Available
36 Dharmendra Kumar Maurya, Shyamali, Shyam Lal Mudavath, Shyam Sundar, Om Prakash Singh (2024) , Leishmania Proteomics: Insight into Diagnostics and Vaccine Development , Springer Nature Singapore, Springer,-,NA,81-107 IF - NA.
35 Karole, A.; Dinakar, Y.H.; Sagar, P.; Mudavath, S.L.* (2024) , Self-assembled nano-micelles for oral delivery of luteolin utilizing intestinal lymphatic pathway targeting pancreatic cancer , Nano Scale, RSC,Just accepted,, IF - 6.7.
34 Arora, K., Dhruw, B., PM, S., Madhukar, P., Sundar, S., Mudavath, S.L.* (2024) , Dual drug delivery for augmenting bacterial wound complications via tailored ultradeformable carriers , Bioconjugate Chemistry, ACS,Just accepted,, IF - 4.7.
33 Kanika Arora, PM Sherilraj, KA Abutwaibe, Bharti Dhruw, Shyam Lal Mudavath* (2024) , Glycans and Biological Macromolecules: A Comprehensive review on advancing Biomedical frontiers , International Journal of Biological Macromolecules, Elsevier,Just accepted,, IF - 8.2.
32 Yadagiri, G.; Arora, K.; Singh, A.; Mudavath, S.L.* (2023) , Immunotherapy and immunochemotherapy in combating visceral leishmaniasis , Front. Med. , Frontiers,10,NA,1096458 IF - 3.9.
31 Dinakar, Y.H.; Karole, A.; Parvez, S.; Jain, V.; Mudavath, S.L.* (2023) , Folate receptor targeted NIR cleavable liposomal delivery system augment penetration and therapeutic efficacy in breast cancer , Biochimica et Biophysica Acta (BBA) - General Subjects, Elsevier,130396,NA,1867 IF - 3.0.
30 Yadagiri, G.; Mudavath, S.L.* (2023) , Current challenges and nanotechnology-based pharmaceutical approaches for the treatment and control of visceral leishmaniasis , Recent Advances in Pharmaceutical Innovation and Research, Springer Nature Singapore,ISBN-13,NA,9789819923014 IF - NA.
29 Arora, K., Sherilraj, P.M., Mudavath, S.L.* (2023) , Multifunctional bioconjugates and their utilities , Comprehensive Analytical Chemistry, Elsevier,ISSN 0166-526X,NA,NA IF - NA.
28 Javaid, A.; Singh, A.; Shabi Parvez, S.; Negi, M.; Mudavath, S.L.* (2023) , Carboxymethyl tamarind seed polysaccharide nanoparticles as a potent mucomimetic and biocompatible oral nanocarrier , Colloids and Surfaces A: Physicochemical and Engineering Aspects, Elsevier,682,132889, IF - 5.2.
27 Javaid A, KA Abutwaibe, Sharma KK, PM Sherilraj, Verma A, Mudavath SL* (2023) , Niacin-Loaded Liquid Crystal Nanoparticles Ameliorate Prostaglandin D2-Mediated Niacin-Induced Flushing and Hepatotoxicity , ACS Applied Nano Materials, ACS,,, IF - 5.9.
26 Singh, A.; Yadagiri, G.; Negi, M.; Kushwaha, A.K.; Singh, O.P.; Sundar, S.; Mudavath, S.L*. (2022) , Carboxymethyl chitosan modified lipid nanoformulations as a highly efficacious and biocompatible oral anti-leishmanial drug carrier system , Int J Biol Macromol., Elsevier,204,NA,373-385 IF - 8.2.
25 Karole, A.; Parvez, S.; Thakur, R.S.; Mudavath, S.L.* (2022) , Effervescent based nano-gas carrier enhanced the bioavailability of poorly aqueous soluble drug: A comprehensive mechanistic understanding , Journal of Drug Delivery Science and Technology, Elsevier,69,NA,103167 IF - 5.0.
24 Parvez, S.; Karole, A.; Mudavath, S.L.* (2022) , Transport Mechanism of Hydroxy-propyl-beta- cyclodextrin modified Solid Lipid Nanoparticles across human epithelial cell for the oral absorption of Antileishmanial drugs , Biochimica et Biophysica Acta (BBA) - General Subjects, Elsevier,1866,NA,130157 IF - 3.0.
23 Parvez, S.; Karole, A.; Mudavath, S.L.* (2022) , Fabrication, Physicochemical characterization and In vitro anticancer activity of Nerolidol encapsulated Solid Lipid Nanoparticles in Human Colorectal Cell Line , Colloids and Surfaces B: Biointerfaces, Elsevier,215,NA,112520 IF - 5.8.
22 Singh, A.; Yadagiri, G.; Javaid, A.; Sharma, S.S.; Verma, A.; Singh, O.P.; Sundar, S.; Mudavath, S.L.* (2022) , Hijacking the intrinsic Vitamin B12 pathway for oral delivery of nanoparticles ensuing an enhanced in vivo anti-leishmanial activity , Biomater. Sci. , RSC,10,NA,5669-5688 IF - 6.6.
21 Parvez, S.; Karole, A; Dinakar, Y.H.; Mudavath, S.L.* (2022) , Nanoformulation mediated silencing of P-gp efflux protein for the efficient oral delivery of anti-leishmanial drugs , Journal of Drug Delivery Science and Technology, Elsevier,78,NA,103959 IF - 5.0.
20 Dinakar, Y.H.; Kumar, H.; Mudavath, S.L.; Jain, R.; Ajmeer, R.; Jain, V. (2022) , Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors , Life Sciences , Elsevier,309,NA,120996 IF - 6.1.
19 Dinakar, Y.H.; Karole, A.; Parvez, S.; Jain, V.; Mudavath, S.L.* (2022) , Organ-restricted delivery through stimuli-responsive nanocarriers for lung cancer therapy , Life Sciences, Elsevier,310,NA,121133 IF - 6.1.
18 Arora, K., Singh, A., Javaid, A., Mudavath, S.L.* (2022) , Promising Functional Supramolecules in Antiviral Drugs , Pharmaceutical Applications of Supramolecules, Springer, Cham. ,NA,NA,NA IF - NA.
17 Singh, B.; Shyamali, Maurya, D.K.; Kumar, R.; Chauhan, S.B.; Mudavath, S.L.; Meena, R.N.; Sundar, S.; Singh, O.P. (2022) , Vaccine human clinical trial, System Vaccinology , The History, the Translational Challenges and the Future, Elsevier,NA,NA,NA IF - NA.
16 Gedda, M.R.; Madhukar, P.; Shukla, A.; Mudavath, S.L.; Srivastava, O.N.; Singh, O. P.; Sundar, S. (2021) , Nanodiagnostics in Leishmaniasis: A New Frontier for Early Elimination , Wiley Interdiscip Rev Nanomed Nanobiotechnol. , Wiley,13,2,e1675 IF - 8.6.
15 Pushpendra, Suryawanshi, I.; Kalia, R.; Kunchala, R.K.; Mudavath, S.L.; Boddu, S. N. (2021) , Detection of Latent Fingerprints using Luminescent Gd0.95Eu0.05PO4 Nanorods , Journal of Rare Earth, Elsevier,40,NA,572-578 IF - 4.9.
14 Pushpendra, Suryawanshi, I.; Srinidhi, S.; Singh, S.; Kalia, R.; Kunchala, R.K.; Mudavath, S.L.; Boddu, S. N. (2021) , Downshifting and upconversion dual mode emission from lanthanide doped GdPO4 nanorods for unclonable anti-counterfeiting. , Materials Today Communications, Elsevier,26,NA,102144 IF - 3.8.
13 Parvez, S.; Yadagiri, G.; Arora, K.; Javaid, A.; Kushwaha, A.K.; Singh, O.P.; Sundar, S.; Mudavath, S.L.* (2021) , Coalition of biological agent (melatonin) with chemotherapeutic agent (amphotericin B) for combating visceral leishmaniasis via oral administration of modified solid lipid nanoparticles , ACS Biomaterials Science , ACS,9,NA,2902-2910 IF - 5.8.
12 Yadagiri, G.; Mudavath, S.L.* (2020) , Enkephalins as a therapeutic intervention for visceral leishmaniasis. , Medical Hypotheses, Elsevier,144,NA,109956 IF - 4.7.
11 Gedda, M.R.; Madhukar, P.; Vishwakarm, A.K.; Verma, V.; Kushwaha, A.K.; Yadagiri, G.; Mudavath, S.L.; Singh, O.P.; Srivastava, O.N.; Sundar, S. (2020) , Evaluation of Safety and Antileishmanial efficacy of Amine Functionalized Carbon-based Composite Nanoparticle appended with Amphotericin B: An In vitro and Preclinical Study. 2020, 8:510. , Front. Chem., Frontiers,8,510,1-9 IF - 5.5.
10 Parvez, S.; Yadagiri, G.; Rao Gedda, M.R.; Singh, A.; Singh, O.P.; Verma, A.; Sundar, S.; Mudavath, S.L.* (2020) , Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: An effective oral combination against experimental murine visceral leishmaniasis , Scientific Reports, Springer Nature,10,1,12243 IF - 4.6.
9 Singh, A.; Sharma, S.; Yadagiri, G.; Parvez, S.; Koratkar, N.; Singh, O.P.; Sundar, S.; Vijayakumar Shanmugam, V*.; Mudavath, S.L.* (2020) , Sensible graphene oxide differentiates macrophages and Leishmania: A Bio-nano interplay in attenuating intracellular parasite , RSC Advances, RSC,10,NA,27502–27511 IF - 3.9.
8 Singh, A.; Yadagiri, Y.; Parvez, S.; Singh, O.P.; Verma, A.; Sundar, S.; Mudavath, S.L.* (2020) , Formulation, characterization, and in vitro anti-leishmanial evaluation of amphotericin b loaded solid lipid nanoparticles coated with vitamin B12-stearic acid conjugate , Mater Sci Eng C Mater Biol Appl. , Elsevier,117,NA,111279 IF - 8.457.
7 Parvez, S.; Yadagiri, G.; Karole, A.; Singh, O.P.; Verma, A.; Sundar, S.; Mudavath, S.L.* (2020) , Recuperating the biopharmaceutical aspects of amphotericin B and paromomycin using a chitosan functionalized nanocarrier via oral route for enhanced anti-leishmanial activity , Front. Cell. Infect. Microbiol., Frontiers,10,NA,570573 IF - 5.7.
6 Singh, O.P.; Gedda, M.R.; Mudavath, S.L.; Srivastava, O.N.; Sundar, S. (2019) , Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application. , Nanomedicine (Lond)., Future Medicine,14,NA,1911-1927 IF - 5.0.
5 Chaubey, P.; Mishra, B.; Mudavath, S. L.; Patel, R.R.; Chaurasia, S.; Sundar, S.; Suvarna, V.; Monteiro, M. (2018) , Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against Leishmania donovani , Int J Biol Macromol., Elsevier,111,NA,109-120 IF - 8.2.
4 Vishwakarma, N.K.; Patel, V.K.; Gundampati, R.K.; Mudavath, S.L.; Gupta, T.; Ramesh, K.; Jana, K.K.; Dutta, P.K.; Maiti, P.; Mishra, N.; Jagannadham, M.V.; Sundar, S.; Ray, B. (2015) , Galactosylated Chitosan for Enhanced and Efficient Antimicrobial and Antileishmanial Activities: A Novel Approach. , Asian Chitin J., SSM International Publication,11,NA,11-18 IF - NA.
3 Saudagar, P.; Mudavath, S.L.; Saha, P.; Saikia, A.K.; Sundar, S.; Dubey, V.K. (2014) , In vivo assessment of antileishmanial property of 4-(4, 4, 8-Trimethyl 7-oxo-3-oxabicyclo [3.3.1] non-2-yl)-benzoic acid methyl ester, an oxabicyclo [3.3.1] nonanones, in hamster model , Letters in Drug Design , Bentham Science,11,7,937-939 IF - 1.0.
2 Mudavath S.L.; Talat, M.; Rai, M.; Srivastava, O.N.; Sundar, S. (2014) , Characterization and evaluation of amine modified graphene Amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies , Drug Des Devel Ther. , Dove Press,8,NA,1235-1247 IF - 4.8.
1 Kumar, D.; Khanal, B.; Tiwary, P.; Mudavath, S.L.; Tiwary, N.K.; Singh, R.; Koirala, K.; Boelaert, M.; Rijal, S.; Sundar, S (2013) , Comparative Evaluation of Blood and Serum Samples in Rapid Immunochromatographic Tests for Visceral Leishmaniasis , Journal of Clinical Microbiology, American Society for Microbiology,51,12,3955-3959 IF - 9.4.
Title Year Duration Amount(In Lakhs) PI/I
Dual action antibiotics in mesoporous silica coated upconversion mediated photodynamic therapy against Methicillin-resistant Staphylococcus aureus 2023 3 58 PI
Bio-degradable nanofiber encapsulated biofertilizer to enhance phosphorous and other micro nutrient uptake in rice 2022 3 99 Co-PI
Citric acid induced self-assemble bubble carrier system to enhance the oral bioavailability of poorly aqueous soluble drugs 2021 3 47 PI
Development of modified lipid nanovesicles based oral drug delivery system for the treatment of visceral leishmaniasis 2018 3 50 PI
Transforming advances in nanotechnology and drug delivery into biomedical applications

Our research thrusts is to engineering delivery systems for poorly water soluble drugs towards therapeutic clinical applications primarily, against neglected infectious diseases. We focus on the development of nanomedicines based on biological nanomaterials with considerable priority on interface between in vitro and in vivo studies and how logically designed and engineered drug delivery systems can be translated into clinically effective therapeutics. Also, our current team is engaged in resolving obstacles in predominant therapeutics of varicose veins, degrees of wound healing and antibiotic resistance. We aim to develop transdermal patches which could deliver active pharmaceutical ingredients (APIs) via fabricated nanocarriers. The budding research would drive on microfluidic platforms specifically designed for controlled and sustained drug release. Conjointly, our group plans to unravel the effect of upconversion nanoparticles in light sensitive medicines. Our delighted obsession is expanding the bounds of knowledge and possibilities in interdisciplinary areas of research and discoveries.

From INST

Alumini

  1. Dr. Shabi Parvez (Ph.D. awarded in 2022)
  2. Dr. Aakriti Singh  (Ph.D. awarded in 2023)

Ph.D ongoing

  1. Ms. Archan Karole
  2. Mr. Aaqib Javaid
  3. Ms. Kanika Arora
  4. Mr. Sherilraj PM